Akpinar, S. Et Al. 2022. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.22, no.3 , 169-173.

Akpinar, S., Dogu, M. H., ÇELİK, S., Ekinci, O., Hindilerden, I. Y., Dal, M. S., ... Davulcu, E. A.(2022). The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.22, no.3, 169-173.

Akpinar, Seval Et Al. "The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.22, no.3, 169-173, 2022

Akpinar, Seval Et Al. "The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.22, no.3, pp.169-173, 2022

Akpinar, S. Et Al. (2022) . "The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.22, no.3, pp.169-173.

@article{article, author={Seval Akpinar Et Al. }, title={The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2022, pages={169-173} }